Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Technologies - Radioactive and Nonradioactive Probes: Special Session

The 5-HT2A receptor and serotonin transporter in ecstasy users evaluated with [11C]MDL 100907 and [11C]DASB

Nina Urban, Ragy Girgis, Peter Talbot, Mark Slifstein, Xiaoyan Xu, Judy Thompson, Lawrence Kegeles, Anissa Abi-Dargham and Marc Laruelle
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 26;
Nina Urban
1Psychiatry, Columbia University, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ragy Girgis
1Psychiatry, Columbia University, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Talbot
2Psychiatry, University of Manchester, Manchester, United Kingdom
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Slifstein
1Psychiatry, Columbia University, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaoyan Xu
1Psychiatry, Columbia University, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Judy Thompson
1Psychiatry, Columbia University, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lawrence Kegeles
1Psychiatry, Columbia University, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anissa Abi-Dargham
1Psychiatry, Columbia University, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marc Laruelle
1Psychiatry, Columbia University, New York, NY
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

26

Objectives The potent serotonin (5HT) releaser MDMA (3,4-methylenedioxy-N-methamphetamine, “ecstasy”) causes 5HT depletion with neurotoxic loss of serotonin transporters (SERT) and upregulation of 5HT2A receptors in animal models. Some, but not all, imaging studies in human ecstasy users have observed decreased SERT binding. In vivo evidence for MDMA-induced changes in postsynaptic 5HT2A receptors in humans has been scarce. This is the first study investigating both components of the 5HT system in the same group of users.

Methods Positron emission tomography (PET) using the specific SERT ligand [11C]DASB and the selective 5HT2A receptor ligand [11C]MDL 100907 was performed in 13 detoxified and chronic moderate ecstasy users (XTC) and 13 drug naïve healthy controls (HC). Regional SERT availability and 5HT2A receptor availability were analyzed using a two-tissue compartment model (2TCM) with arterial input function. Relationships between parameters of ecstasy use and BPND were analyzed using Pearson correlation coefficients.

Results Compared to HC, XTC displayed significantly increased 5HT2A receptors availability in cortical regions (DLPFC and parietal cortex, p<0.05), and decreased SERT availability in cortical, but not subcortical, regions (medial prefrontal, temporal and occipital cortex, p<0.05). Parameters of ecstasy use (lifetime use, frequency, abstinence duration) did not significantly correlate with SERT or 5HT2A availability in cortical regions.

Conclusions Our results support that chronic moderate ecstasy use in humans might lead to neurotoxic damage to 5HT nerve terminals in the cortex, and that this neurotoxicity might be associated with compensatory upregulation of postsynaptic 5HT2A receptors. This study adds to the growing body of evidence suggesting the potential detrimental effects of this widely used recreational drug on the 5HT system. Reversibility of these changes upon sustained abstinence remains to be fully documented.

Research Support Funded by NIDA

Back to top

In this issue

Journal of Nuclear Medicine
Vol. 52, Issue supplement 1
May 2011
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The 5-HT2A receptor and serotonin transporter in ecstasy users evaluated with [11C]MDL 100907 and [11C]DASB
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The 5-HT2A receptor and serotonin transporter in ecstasy users evaluated with [11C]MDL 100907 and [11C]DASB
Nina Urban, Ragy Girgis, Peter Talbot, Mark Slifstein, Xiaoyan Xu, Judy Thompson, Lawrence Kegeles, Anissa Abi-Dargham, Marc Laruelle
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 26;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The 5-HT2A receptor and serotonin transporter in ecstasy users evaluated with [11C]MDL 100907 and [11C]DASB
Nina Urban, Ragy Girgis, Peter Talbot, Mark Slifstein, Xiaoyan Xu, Judy Thompson, Lawrence Kegeles, Anissa Abi-Dargham, Marc Laruelle
Journal of Nuclear Medicine May 2011, 52 (supplement 1) 26;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Technologies - Radioactive and Nonradioactive Probes: Special Session

  • The development of PET/MRI dual modality probe based on IO nanoparticle for pancreatic beta-cell imaging
  • Noninvasive determination of the beta cell mass in rats by SPECT with 111In-DTPA-Exendin-3
  • In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor
Show more Molecular Targeting Technologies - Radioactive and Nonradioactive Probes: Special Session

Center for Molecular Imaging Innovation & Translation (CMIIT) Young Investigator Award Symposium

  • The development of PET/MRI dual modality probe based on IO nanoparticle for pancreatic beta-cell imaging
  • Noninvasive determination of the beta cell mass in rats by SPECT with 111In-DTPA-Exendin-3
  • In vivo imaging of transplanted islets with 64Cu-DO3A-VS-Cys40-Exendin-4 by targeting GLP-1 receptor
Show more Center for Molecular Imaging Innovation & Translation (CMIIT) Young Investigator Award Symposium

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire